The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abatacept in the treatment of patients with psoriatic arthritis: Results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial
Abstract
Objective: To assess the safety and efficacy of abatacept, a selective T cell costimulation modulator, in patients with psoriatic arthritis (PsA). Methods: In this 6‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II study, 170 PsA patients with a psoriasis target lesion (TL) ≥2 cm who had previously taken disease‐modifying antirheumatic drugs (DMARDs), including anti–tumor necrosis factor (anti‐TNF) agents, were randomized (1:1:1:1) to receive placebo or abatacept at doses of 3 mg/kg, 10 mg/kg, or 30/10 mg/kg (2 initial doses of 30 mg/kg, followed by 10 mg/kg) on days 1, 15, and 29 and then once every 28 days thereafter. The primary end point was the American College of Rheumatology 20% criteria for improvement (ACR20 response) on day 169. Other key end points were magnetic resonance imaging (MRI) scores for joint erosion, osteitis, and synovitis, scores on the Health Assessment Questionnaire (HAQ) and the Short Form‐36 (SF‐36) health survey, the investigator's global assessment of psoriasis, the TL score, and the Psoriasis Area and Severity Index (PASI) score. Results: Proportions of patients achieving an ACR20 response were 19%, 33%, 48%, and 42% in the placebo, the abatacept 3 mg/kg, the abatacept 10 mg/kg, and the abatacept 30/10 mg/kg groups, respectively. Compared with placebo, improvements were significantly higher for the abatacept 10 mg/kg (P = 0.006) and 30/10 mg/kg (P = 0.022) groups, but not for 3 mg/kg group (P = 0.121). All abatacept regimens resulted in improved MRI, HAQ, and SF‐36 scores, with 10 mg/kg showing the greatest improvements. Improvements in the TL and PASI scores were observed in all abatacept arms; a response according to the investigator's global assessment was seen only with 3 mg/kg of abatacept. The safety profiles were similar among the treatment arms. Conclusion: The results of this study suggest that 10 mg/kg of abatacept, the approved dosage for rheumatoid arthritis and juvenile idiopathic arthritis, may be an effective treatment option for PsA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Taylor, W., Gladman, D., Helliwell, P., Marchesoni, A., Mease, P., & Mielants, H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21972 · Cited by 3,746
Self-citationAmerican college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
Fries, J. F., Spitz, P. W., & Young, D. Y. (1982) · PubMed · Cited by 1,318
Russo, J., Trujillo, C. A., Wingerson, D., Decker, K., Ries, R., Wetzler, H., & Roy-Byrne, P. (1998) · Medical Care · doi:10.1097/00005650-199805000-00015 · Cited by 1,308
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Self-citationMease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Self-citationSamsa, G., Edelman, D., Rothman, M. L., Williams, G. R., Lipscomb, J., & Matchar, D. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915020-00003 · Cited by 903
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20335 · Cited by 882
Self-citationKremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Self-citationInfliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
Antoni, C., Krueger, G. G., de Vlam, K., Birbara, C., Beutler, A., Guzzo, C., Zhou, B., Dooley, L. T., & Kavanaugh, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032268 · Cited by 715
Østergaard, M., PETERFY, C. G., Conaghan, P. G., McQueen, F. M., Bird, P., Ejbjerg, B., Shnier, R., O’Connor, P., Klarlund, M., Emery, P., et al. (2003) · PubMed · Cited by 700
Antoni, C. E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20967 · Cited by 640
Self-citationPsoriatic Arthritis (PSA) - An Analysis of 220 Patients
(1987) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068085 · Cited by 639
Kavanaugh, A., McInnes, I., Mease, P., Krueger, G. G., Gladman, D., Gomez‐Reino, J., Papp, K., Zrubek, J., Mudivarthy, S., Mack, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24403 · Cited by 602
Self-citationCTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Epidemiology of psoriatic arthritis in the population of the United States
Gelfand, J. M., Gladman, D. D., Mease, P. J., Smith, N., Margolis, D. J., Nijsten, T., Stern, R. S., Feldman, S. R., & Rolstad, T. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.03.046 · Cited by 596
Self-citationTreatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Ruperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio-Pérez, N., Silva, C. A., Abud-Mendoza, C., Burgos-Vargas, R., Gerloni, V., Melo-Gomes, J. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60998-8 · Cited by 560
Self-citationTreatment recommendations for psoriatic arthritis
Ritchlin, C. T., Kavanaugh, A., Gladman, D. D., Mease, P. J., Helliwell, P., Boehncke, W.-H., de Vlam, K., Fiorentino, D., FitzGerald, O., Gottlieb, A. B., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094946 · Cited by 554
Self-citationKremer, J. M., Dougados, M., Emery, P., Durez, P., Sibilia, J., Shergy, W., Steinfeld, S., Tindall, E., Becker, J., Li, T., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21201 · Cited by 444
Self-citationThe epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
Shbeeb, M. I., Uramoto, K. M., Gibson, L. E., O’Fallon, W. M., & Gabriel, S. E. (2000) · PubMed · Cited by 392
Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.681 · Cited by 318
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., Li, T., Schmidely, N., Le Bars, M., & Dougados, M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074773 · Cited by 264
Self-citationvan Kuijk, A. W. R., Reinders-Blankert, P., Smeets, T. J. M., Dijkmans, B. A. C., & Tak, P. P. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.050963 · Cited by 201
Self-citationGenovese, M. C., Mease, P. J., Thomson, G. T. D., Kivitz, A., Perdok, R. J., Weinberg, M. A., Medich, J., & Sasso, E. H. (2007) · PubMed · Cited by 200
Self-citationThe clinical utility of inhibiting CD28‐mediated costimulation
Linsley, P. S., & Nadler, S. G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00780.x · Cited by 162
Genant, H. K., Peterfy, C. G., Westhovens, R., Becker, J.-C., Aranda, R., Vratsanos, G., Teng, J., & Kremer, J. M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.085084 · Cited by 158
Self-citationAntoni, C., Kavanaugh, A., van der Heijde, D. M. F. M., et al. (2008) · PubMed · Cited by 156
Mease, P. J., Gladman, D. D., & Keystone, E. C. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21870 · Cited by 152
Self-citationKraan, M. C., van Kuijk, A. W. R., Dinant, H. J., Goedkoop, A. Y., Smeets, T. J. M., de Rie, M. A., Dijkmans, B. A. C., Vaishnaw, A. K., Bos, J. D., & Tak, P. P. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10543 · Cited by 150
Self-citationvan Kuijk, A. W. R., Gerlag, D. M., Vos, K., Wolbink, G., de Groot, M., de Rie, M. A., Zwinderman, A. H., Dijkmans, B. A. C., & Tak, P. P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091389 · Cited by 95
Self-citationDeveloping a magnetic resonance imaging scoring system for peripheral psoriatic arthritis.
McQueen, F. M., Lassere, M. N., Bird, P., et al. (2007) · PubMed · Cited by 59
Cited by
Ritchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1505557 · Cited by 1,404
Self-citationCD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Coates, L. C., Kavanaugh, A., Mease, P. J., Soriano, E. R., Laura Acosta‐Felquer, M., Armstrong, A. W., Bautista‐Molano, W., Boehncke, W., Campbell, W., Cauli, A., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39573 · Cited by 903
Self-citationOrban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Mandl, P., Navarro-Compán, V, Terslev, L., Aegerter, P., van der Heijde, D., D'Agostino, M. A., Baraliakos, X., Pedersen, S. J., Jurik, A. G., Naredo, E., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206971 · Cited by 572
Metadata
- Authors
- Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., Sigal, L., Teng, J., & Gladman, D.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2011-03-30
- Volume
- 63
- Issue
- 4
- Pages
- 939-948
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1973040111
- Cited by
- 300
- References
- 35
- FWCI
- 18.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.